Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed FCF Margin for 4 consecutive years, with 9.55% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 523685.0% to 9.55% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14.7% through Dec 2025, up 3341.0% year-over-year, with the annual reading at 14.7% for FY2025, 1866.0% up from the prior year.
  • FCF Margin hit 9.55% in Q4 2025 for Axsome Therapeutics, down from 0.58% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 0.58% in Q3 2025 to a low of 5246.4% in Q4 2024.
  • Historically, FCF Margin has averaged 422.0% across 4 years, with a median of 42.46% in 2023.
  • Biggest five-year swings in FCF Margin: crashed -520394bps in 2024 and later soared 523685bps in 2025.
  • Year by year, FCF Margin stood at 113.84% in 2022, then skyrocketed by 63bps to 42.46% in 2023, then plummeted by -12257bps to 5246.4% in 2024, then soared by 100bps to 9.55% in 2025.
  • Business Quant data shows FCF Margin for AXSM at 9.55% in Q4 2025, 0.58% in Q3 2025, and 21.62% in Q2 2025.